SCHEMBL12197225

SCHEMBL12197225

CCOc1ccc(-c2ccc(C3CCC(C(=O)OC4CCC(c5ccc(C)c(F)c5F)CC4)CC3)cc2)c(F)c1F

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 3/20 0.33
▸ FPR2 P25090 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ SSTR5 P35346 3/20 0.32
▸ GLA P06280 1/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ FGFR2 P21802 1/20 0.32
▸ HPGD P15428 1/20 0.31
▸ DGAT1 O75907 1/20 0.31
▸ SOAT1 P35610 1/20 0.31
▸ MAPT P10636 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ ALOX5AP P20292 2/20 0.30
▸ FEN1 P39748 2/20 0.30
▸ PTGDR Q13258 1/20 0.30
▸ PTGDR2 Q9Y5Y4 1/20 0.30
▸ PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12197347 1.00 FFAR4 (0.33) FFAR4FPR2SMN1; SMN2SSTR5GLA
SCHEMBL12196524 0.92 SMN1; SMN2 (0.36) FFAR4FPR2SMN1; SMN2GLAHPGD
SCHEMBL12196535 0.92 SMN1; SMN2 (0.36) FFAR4FPR2SMN1; SMN2GLAHPGD
SCHEMBL14922669 0.91 FPR2 (0.35) FFAR4FPR2SMN1; SMN2SSTR5FGFR1
SCHEMBL12224025 0.91 FPR2 (0.33) FFAR4FPR2SMN1; SMN2SSTR5FGFR1
SCHEMBL10091362 0.89 SMN1; SMN2 (0.38) SMN1; SMN2SSTR5GLAHPGDMAPT
SCHEMBL10091358 0.88 FPR2 (0.36) FFAR4FPR2FGFR1FGFR2ALOX5AP
SCHEMBL12224042 0.88 SSTR5 (0.32) FFAR4FPR2SMN1; SMN2SSTR5
SCHEMBL12197476 0.86 SMN1; SMN2 (0.36) SMN1; SMN2GLAHPGDMAPTPTGDR2
SCHEMBL12197461 0.86 SMN1; SMN2 (0.36) SMN1; SMN2GLAHPGDMAPTPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8435422-B2 Five-ring compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-05-07 — — US disclosed
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE NCAPD3, CCND3, ZKSCAN2 FFAR4 2995/4885FPR2 1970/4885SMN1; SMN2 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback